Deadline: 21-Jul-2026
Pfizer is inviting proposals for quality improvement initiatives focused on implementing shared decision making (SDM) in hemophilia patient care. The programme supports projects that strengthen collaboration between patients, caregivers, and multidisciplinary healthcare teams to improve treatment experiences, patient engagement, and clinical outcomes.
Eligible organizations can apply for funding of up to $30,000 for projects lasting up to 18 months. Applications must be submitted by 21 July 2026.
Overview of the Funding Opportunity
The Pfizer Quality Improvement Request for Proposals (RFP) supports projects that improve hemophilia care through patient-centered approaches and shared decision making.
The initiative encourages healthcare organizations to integrate practical tools, patient-reported outcomes, and collaborative care models that help individuals living with hemophilia actively participate in treatment decisions.
The programme focuses on improving communication and collaboration between:
- Patients
- Caregivers
- Hemophilia treatment teams
- Multidisciplinary healthcare professionals
Key Objectives
The programme aims to:
- Strengthen shared decision making in hemophilia care
- Improve patient engagement and informed decision-making
- Address disparities in healthcare access and treatment outcomes
- Enhance multidisciplinary collaboration
- Improve understanding of treatment burden and quality of life
- Support patient-centered healthcare delivery
Key Focus Areas
Supported projects may focus on:
- Shared decision making (SDM) tools
- Hemophilia care algorithms
- Patient engagement strategies
- Patient-reported outcome (PRO) tools
- Quality improvement initiatives
- Treatment burden assessment
- Healthcare equity and access
- Multidisciplinary care coordination
Projects should contribute to measurable improvements in hemophilia care quality and patient outcomes.
Priority Areas for Projects
The programme encourages initiatives that:
- Integrate SDM tools into routine care
- Improve communication between patients and providers
- Empower patients in disease management decisions
- Evaluate patient-centered treatment outcomes
- Identify barriers related to:
- Geographic disparities
- Gender disparities
- Racial healthcare disparities
Projects may also explore innovative approaches to improving patient experiences and long-term care engagement.
Funding Details
Maximum Grant Amount
Projects may request:
- Up to $30,000
Project Duration
- Maximum Duration: 18 months
Important Dates
Application Deadline
- 21 July 2026
Award Notification
- Expected by 9 September 2026
Anticipated Project Start
- November 2026
Who Can Apply?
Eligible applicants include organizations involved in healthcare education, delivery, and improvement.
Applicants may include:
- Medical schools
- Dental schools
- Nursing schools
- Allied health institutions
- Pharmacy schools
- Healthcare institutions
- Professional organizations
- Government agencies
- Healthcare improvement organizations
Ineligible Applicants
The following are not eligible:
- Individual applicants
- Independent physician practice groups
The Project Lead or Principal Investigator must:
- Be employed or contracted by the applicant organization
Organizations must also be legally able to receive funding directly from Pfizer Inc.
Why Shared Decision Making Matters in Hemophilia Care
Hemophilia treatment often requires long-term management decisions involving:
- Treatment options
- Lifestyle considerations
- Quality of life impacts
- Caregiver involvement
- Monitoring and adherence challenges
Shared decision making helps ensure that patients and caregivers are actively involved in healthcare choices, leading to:
- Better treatment adherence
- Improved patient satisfaction
- Stronger trust between patients and providers
- More personalized care
- Better health outcomes
The programme also supports efforts to reduce inequities within hemophilia care systems.
How the Programme Works
Pfizer will fund quality improvement projects that integrate patient-centered approaches into hemophilia care settings.
Application Process
- Develop a shared decision making or quality improvement proposal
- Identify measurable patient-centered outcomes
- Build multidisciplinary partnerships if relevant
- Prepare implementation and evaluation plans
- Submit the application before the deadline
- Implement approved project activities
Projects should include clear strategies for evaluating impact and patient engagement outcomes.
Tips for a Strong Application
Applicants should:
- Clearly define the healthcare challenge being addressed
- Demonstrate patient-centered approaches
- Include measurable quality improvement outcomes
- Show multidisciplinary collaboration
- Explain how patients and caregivers will be engaged
- Include realistic timelines and evaluation plans
Strong applications usually include:
- Practical SDM implementation methods
- PRO measurement strategies
- Equity and access considerations
- Data collection and evaluation frameworks
- Sustainable care improvement approaches
Frequently Asked Questions (FAQs)
What is the Pfizer Hemophilia Shared Decision Making RFP?
It is a funding opportunity supporting quality improvement projects that strengthen shared decision making in hemophilia care.
How much funding is available?
Projects can receive up to $30,000.
How long can projects last?
Projects may run for up to 18 months.
Who can apply?
Healthcare institutions, professional organizations, medical schools, government agencies, and healthcare improvement organizations can apply.
Are individual physicians eligible?
No, individual applicants and independent physician practice groups are not eligible.
What types of projects are encouraged?
Projects involving SDM tools, patient engagement, PRO implementation, and healthcare equity improvements are encouraged.
When is the application deadline?
Applications must be submitted by 21 July 2026.
Conclusion
The Pfizer Quality Improvement RFP on Shared Decision Making in Hemophilia Patient Care supports healthcare initiatives that strengthen patient-centered care, improve communication, and enhance treatment experiences for individuals living with hemophilia. By funding collaborative and evidence-based approaches, the programme aims to improve care quality, patient engagement, and health outcomes while addressing disparities within the hemophilia community.
The initiative also encourages sustainable improvements in multidisciplinary care delivery and empowers patients to play an active role in healthcare decision-making.
For more information, visit Pfizer.